Fig. 6.

FKBP51 antagonism affects AKT2-AS160 signaling complex. Tissue lysates from 30-day vehicle-treated or SAFit2-treated mice exposed to HFD were immunoprecipitated with anti-AKT2 and anti-FKBP51 and then analyzed by Western blot using FKBP51, (p)AKT2, (p)AS160, and PHLPP1. a, b Immunoprecipitation reactions revealed that SAFit2 treatment increased binding between (p)AKT2 and (p)AS160 in soleus (a) and EDL (b) muscles, while simultaneously decreased binding between FKBP51 and AS160 in both muscle types. For co-immunoprecipitation experiments n = 3 per group. Data are expressed as relative fold change compared to vehicle condition ± SEM. ⁺ P < 0.05, two-tailed t tests for a, b; + significant SAFit2 treatment effect. Supplementary Fig. 15 shows uncropped gel images